The Canadian Ministry of Health on Tuesday banned the sale of Allergan’s Biocell breast implants, suspected of promoting a rare form of cancer.

At the conclusion of a survey, the Canadian government concluded that “the LAGC-AIM [anaplastic large cell lymphoma associated with breast implants] rate in Canada was significantly higher in patients with macrotextured breast implants than in other patients He said in a statement. Of the 26 lymphoma cases observed, 22 “were related to Allergan’s Biocell Breast Implants”.

Allergan is committed to “collaborating with Health Canada”

Health Canada has therefore decided to suspend “Allergan Biocell Breast Implant Approvals”, the only macrotextured breast type sold in the country. The ban “does not target Allergan’s other breast implants,” the government said.

For its part, the company agreed to remove the breast implants concerned from the market. Committed to “collaborate with Health Canada in the implementation of a communication plan to inform surgeons, hospitals, government agencies, medical and professional health associations and patient groups to meet their needs, “said the manufacturer in a separate statement.

Prohibited in France early April
In early April, France had banned, in the name of the “precautionary principle”, several models of breast implants, including models of the American manufacturer Allergan Biocell envelope. It had become the first country to take such a step.

Shortly after, the Canadian government announced its intention to ban the sale of these models if the company failed to prove their safety within 15 days. “It was determined that the information provided by the manufacturer was not sufficient to justify the continued registration of the devices,” Health Canada said.